Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03607695 · ClinicalTrials.gov registry record · NA
Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
A NA study of Parkinson's Disease, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03607695: Completed NA study of Parkinson's Disease, sponsored by VA Office of Research and Development.
NCT03607695 is a NA study of Parkinson's Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 19 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03607695, a NA study of Parkinson's Disease, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The aging Veteran population, together with high exposure to Agent Orange or other herbicides during military service, has made diseases such as Parkinson's disease (PD), currently affecting more than 80,000 Veterans, a major health issue in the Veterans' health system. Mobility and cognitive limitations are a common problem in PD and are associated with significant disability, increased fall risk, reduced quality of life, and increased caregiver burden. While less is known about its benefit on cognition, physical therapy has proven to be an effective treatment to mitigate mobility limitations, though the response to rehabilitation interventions is highly variable. The proposed research will inform the investigators' understanding of the impact of certain genetic profiles associated with learning impairments on motor and cognitive benefits in response to gait rehabilitation, and will provide an important foundation for more personalized and improved gait rehabilitation programs for different subgroups of PD patients.
Primary Outcome
The investigators will use the APDM Movement Monitoring system to assess gait speed (m/s) during straight-line walking as a measure of gait function.
Conditions Studied
Interventions
- OTHER Gait training
Study Locations (1)
Washington
- VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
What the finished NCT03607695 record still lists
NCT03607695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Gait training is the first listed.
NCT03607695 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03607695 about?
NCT03607695 is a clinical study titled "Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease". The aging Veteran population, together with high exposure to Agent Orange or other herbicides during military service, has made diseases such as Parkinson's disease (PD), currently affecting more than 80,000 Veterans, a major health issue in the Veterans' health system. Mobility and cognitive limita...
What is the current status of trial NCT03607695?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2018-02-01. Estimated completion is 2020-06-30.
What conditions does trial NCT03607695 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT03607695?
The interventions under investigation include: Gait training (OTHER).
Who is sponsoring clinical trial NCT03607695?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03607695 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03607695's enrollment target sits among peer trials
19 136th of 158 higher than 23 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
RECRUITING · NA
-
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
RECRUITING · NA
-
Deep Brain Stimulation Therapy in Movement Disorders
RECRUITING · NA
-
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI